<DOC>
	<DOCNO>NCT00339144</DOCNO>
	<brief_summary>The primary objective study determine maximum tolerate dose ( MTD ) maximum administer dose ( MAD ) Dasatinib ( BMS-354825 ) patient Japan .</brief_summary>
	<brief_title>Study Dasatinib ( BMS-354825 ) Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Performance status ( general condition ) specify Eastern Cooperative Oncology Group : 02 Histologic cytologic diagnosis solid tumor progress follow standard therapy ( include relapse disease ) standard therapy exist . men woman , age 20 woman childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study 3 month study manner risk pregnancy minimize Adequate hepatic function Participants eligible willing undergo transplantation pre study . Women pregnant breastfeed know brain metastasis symptom brain metastasis Uncontrolled significant bleeding disorder unrelated primary tumor Dementia mental illness would prohibit understanding give informed consent . Severe allergy drug require appropriate supportive care patient study . History gastrointestinal surgery digestive disorder potential inhibit absorption study drug . Pleural effusion &gt; Grade 1 Patient dysphagia Does agree blood/blood product transfusion ( ) Donated blood 200 mL within 4 week prior start study therapy Medication know risk cause Torsade de point Participants compulsorily detain legal reason treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Solid tumor ( include relapse disease ) refractory standard therapy effective standard therapy exists</keyword>
</DOC>